Core Insights - TONMYA (cyclobenzaprine HCl sublingual tablets) is the first new FDA-approved treatment for fibromyalgia in adults in over 15 years, launched commercially in the U.S. in November 2025 [1] - The formulation is designed for rapid transmucosal absorption, bypassing first-pass liver metabolism, which enhances the durability of analgesic response compared to traditional oral cyclobenzaprine [1][2] - Clinical studies indicate that TONMYA provides a durable analgesic benefit and is generally well tolerated among fibromyalgia patients [2][5] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully integrated biotechnology company focused on central nervous system (CNS) and immunology treatments, with TONMYA as its flagship product [9] - The company is also developing other treatments, including those for major depressive disorder and acute stress disorder, leveraging its proprietary formulations [9] Product Details - TONMYA utilizes a patented sublingual formulation that enhances drug exposure during sleep while minimizing side effects associated with the active metabolite norcyclobenzaprine [8] - The product is indicated for the treatment of fibromyalgia in adults and is expected to have U.S. market exclusivity until 2034/2035 due to multiple patents [8] Clinical Study Findings - Study 1 demonstrated that the potassium phosphate dibasic formulation of TONMYA achieved a 154% relative bioavailability compared to oral immediate-release cyclobenzaprine, with a significantly shorter absorption lag [3] - Study 2 confirmed the absence of food effects on pharmacokinetic parameters and characterized the active metabolite's elimination half-life as approximately 60 hours [4] Market Context - Fibromyalgia affects an estimated 6-12 million adults in the U.S., predominantly women, and is characterized by chronic pain and other debilitating symptoms [7] - There is a noted dissatisfaction with currently marketed products for fibromyalgia, highlighting the potential market opportunity for TONMYA [7]